Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis acquires cancer drug developer MorphoSys for $2.9 bln
04:55pm, Monday, 05'th Feb 2024
Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)
Valeo Pharma amends Novartis eye treatment distribution agreement
08:31am, Monday, 05'th Feb 2024
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has unveiled changes to a seven-year agreement with Novartis Pharmaceuticals for the distribution of its eye treatment. Xiidra, a treatment for dry eye, will b
It's shaping up to be a great quarter for Europe's biggest companies — no thanks to Europe.
03:59am, Monday, 05'th Feb 2024
Fourth-quarter earnings season in Europe is still in its early days, but the largest companies on the Continent are mostly hitting their stride.
3 Fabulous Dividend Stocks to Buy in February
05:50am, Sunday, 04'th Feb 2024
AbbVie is a Dividend King with plenty of growth potential left. Novartis offers investors a high dividend yield and strong prospects.
4 Large Drug Stocks Trying to Survive the Industry Challenges
09:51am, Friday, 02'nd Feb 2024
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retainin
Novartis CEO Vasant Narasimhan on Q4 earnings miss
12:45pm, Thursday, 01'st Feb 2024
Novartis CEO Vasant Narasimhan joins 'Money Movers' to discuss the company's quarterly earnings results, the company's warning about losing exclusivity in some products, and if the sector will be acti
Novartis Stock Slumps After Drugmaker's Earnings, Guidance Fall Short of Expectations
02:10pm, Wednesday, 31'st Jan 2024
Novartis (NVS) announced fourth-quarter results and guidance Wednesday that fell short of analyst's expectations, and the company also ended a study on an experimental blood cancer treatment. American
Novartis AG (NVS) Q4 2023 Earnings Call Transcript
12:39pm, Wednesday, 31'st Jan 2024
Novartis AG (NVS) Q4 2023 Earnings Call Transcript
Novartis (NVS) Q4 Earnings Miss on Higher Costs, Sales Lag
11:50am, Wednesday, 31'st Jan 2024
Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.
Novartis (NVS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Wednesday, 31'st Jan 2024
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Stre
Novartis CEO: Growth drivers performing well, but product exclusivity losses creating headwinds
06:00am, Wednesday, 31'st Jan 2024
Vas Narasimhan, CEO of Novartis, discusses fourth-quarter results, weight loss drugs and the company's U.S. targets.
Novartis eyes 5% annual sales growth through 2028
01:16am, Wednesday, 31'st Jan 2024
Switzerland's Novartis on Wednesday updated its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Monday, 29'th Jan 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:21am, Friday, 26'th Jan 2024
Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qu
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
12:41pm, Wednesday, 24'th Jan 2024
Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
